InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
3
Disclosed sells
0
T+90 hit rate
75%
T+90 mean return
+19.0%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by INGRAM DOUGLAS S, Chairman & CEO. Director active across 2 companies, notably Sarepta Therapeutics, Inc.. In total, 6 disclosures have been recorded. Breakdown: 3 buys · 0 sell. Total volume traded: €4.3m. Activity tracked since 26 June 2021. The latest transaction was disclosed on 6 February 2025 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations6 total
38,396 shares@ US$20.09100.0% of flowCommon StockSEC:0001628280-25-004478:0
10,081 shares@ US$78.5711.2% of flowCommon StockSEC:0001209191-23-054441:0
Ideal exit: 30 Jul 2024 (T+270)
25,026 shares@ US$79.940.078% mcap29.8% of flowCommon StockSEC:0001209191-21-065246:0
Ideal exit: 14 Aug 2022 (T+270)
25,026 shares@ US$79.9426.5% of flowCommon StockSEC:0001209191-21-065246
Ideal exit: 14 Aug 2022 (T+270)
17,812 shares@ US$80.400.053% mcap20.2% of flowCommon StockSEC:0001209191-21-043582:0
17,812 shares@ US$80.4018.0% of flowCommon StockSEC:0001209191-21-043582
6 of 6 declarations
About INGRAM DOUGLAS S
Douglas S. Ingram is the President and CEO of Sarepta Therapeutics, Inc. He leads the company with a strategic vision, overseeing operations and business development. His leadership is essential for innovation and growth at Sarepta Therapeutics, Inc.
